Jane Street Group LLC Has $258,000 Holdings in Arbutus Biopharma Co. (NASDAQ:ABUS)

Jane Street Group LLC cut its holdings in Arbutus Biopharma Co. (NASDAQ:ABUS) by 67.1% during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 66,910 shares of the biopharmaceutical company’s stock after selling 136,488 shares during the period. Jane Street Group LLC’s holdings in Arbutus Biopharma were worth $258,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also modified their holdings of ABUS. Charles Schwab Investment Management Inc. lifted its position in Arbutus Biopharma by 218.5% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,212,246 shares of the biopharmaceutical company’s stock worth $4,667,000 after purchasing an additional 831,663 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new stake in Arbutus Biopharma during the third quarter worth about $754,000. State Street Corp lifted its position in Arbutus Biopharma by 50.2% during the third quarter. State Street Corp now owns 4,407,133 shares of the biopharmaceutical company’s stock worth $16,967,000 after purchasing an additional 1,472,652 shares during the period. Rubric Capital Management LP bought a new stake in Arbutus Biopharma during the second quarter worth about $5,195,000. Finally, Wellington Management Group LLP lifted its position in Arbutus Biopharma by 4.6% during the third quarter. Wellington Management Group LLP now owns 496,818 shares of the biopharmaceutical company’s stock worth $1,913,000 after purchasing an additional 21,807 shares during the period. 43.79% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the stock. Chardan Capital reissued a “buy” rating and issued a $5.00 target price (up previously from $4.50) on shares of Arbutus Biopharma in a report on Wednesday, November 20th. HC Wainwright reissued a “buy” rating and issued a $5.00 target price on shares of Arbutus Biopharma in a report on Monday, November 18th. Finally, JMP Securities increased their target price on shares of Arbutus Biopharma to $5.00 and gave the stock a “buy” rating in a report on Wednesday, November 6th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat, Arbutus Biopharma presently has an average rating of “Moderate Buy” and an average price target of $5.50.

Arbutus Biopharma Trading Down 1.8 %

ABUS stock opened at $3.29 on Friday. The firm has a 50-day moving average price of $3.48 and a 200-day moving average price of $3.70. The stock has a market capitalization of $623.43 million, a P/E ratio of -7.65 and a beta of 1.78. Arbutus Biopharma Co. has a 12 month low of $2.21 and a 12 month high of $4.72.

Arbutus Biopharma Company Profile

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression.